JUPITER, Fla., Oct. 05, 2023 Dyadic International, Inc. , a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein.
Dyadic s C1 Platform Selected by the Vaccine and Immunotherapy Center ( VIC ) at Massachusetts General Hospital as Part of VIC s $5 88 Million Award by U S DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms
Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended. | March 31, 2023
/PRNewswire/ Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study 098 demonstrated.